Newsletter Archive

41. 10.30.24 -- A "Flight Plan" For Achieving These 3 mRNA Development Milestones 10/30/2024
    10/30/24 Advancing RNA Newsletter
42. 10.28.24 -- Nanoparticle Enabled Formulation And Drug Delivery Solutions 10/28/2024
    10/28/24 Advancing RNA Newsletter
43. 10.24.24 -- Are We Really Living In An mRNA Regulatory "Desert"? 10/24/2024
    10/24/24 Advancing RNA Newsletter
44. 10.17.24 -- Resources For Trouble-Free Validation 10/17/2024

    10/17/24 Advancing RNA Newsletter

45. 10.16.24 -- Shifting Scales: Considerations For Small-Scale mRNA Production 10/16/2024
    10/16/24 Advancing RNA Newsletter
46. 10.09.24 -- Tips For Addressing Vaccine Demand – No Matter Your Therapeutic Background 10/9/2024

    10/09/24 Advancing RNA Newsletter

47. 10.09.24 -- One Unspoken Issue With FDA's Platform Designation 10/9/2024
    10/09/24 Advancing RNA Newsletter
48. 10.02.24 -- FDA's Platform Guidance Raises Questions For mRNA Makers 10/2/2024
    10/02/24 Advancing RNA Newsletter
49. 09.26.24 -- Industrializing mRNA Therapeutics 9/26/2024

    09/26/24 Advancing RNA Newsletter

50. 09.25.24 -- Pivoting To RNA With Circio's Dr. Erik Digman Wiklund 9/25/2024
    09/25/24 Advancing RNA Newsletter